Cargando…

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis

BACKGROUND: It remains unknown what is the optimal front-line choice for advanced non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) fusion. METHODS: We conducted a systematic review and network meta-analysis of randomized phase III clinical trials comparing two or more treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Yaokai, Jiang, Tao, Wu, Xiangrong, Peng, Haoxin, Ren, Shengxiang, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403455/ https://www.ncbi.nlm.nih.gov/pubmed/36032351 http://dx.doi.org/10.1177/17588359221116607

Ejemplares similares

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022)

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis
por: Zhu, Yixiang, et al.
Publicado: (2023)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
por: Lin, Liping, et al.
Publicado: (2017)

Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
por: Zhang, Nan, et al.
Publicado: (2018)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis
por: Cheng, Ji, et al.
Publicado: (2019)

Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
por: Zhang, Xia, et al.
Publicado: (2017)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
por: Cavanna, Luigi, et al.
Publicado: (2019)

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

The prognostic value of long non coding RNAs in cervical cancer: A meta-analysis
por: Cui, Xiangrong, et al.
Publicado: (2017)

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
por: Soo, Ross A., et al.
Publicado: (2018)

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis
por: De Mello, Ramon Andrade, et al.
Publicado: (2017)

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
por: Alanazi, Abdullah, et al.
Publicado: (2020)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
por: Han, Yue, et al.
Publicado: (2021)

First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
por: Fong, Khi Yung, et al.
Publicado: (2022)

Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis
por: Mao, Xiaowei, et al.
Publicado: (2017)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
por: Li, Mengjie, et al.
Publicado: (2022)

MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis
por: Huang, Xing, et al.
Publicado: (2017)

Long non-coding RNAs function as novel predictors and targets of non-small cell lung cancer: a systematic review and meta-analysis
por: Xiong, Yanlu, et al.
Publicado: (2018)

Genetic polymorphisms in pre-miRNAs predict the survival of non-small-cell lung cancer in Chinese population: a cohort study and a meta-analysis
por: Xia, Lingzi, et al.
Publicado: (2017)

Prognostic Value of Pretreatment D-Dimer Level in Small-Cell Lung Cancer: A Meta-Analysis
por: Li, Jialong, et al.
Publicado: (2021)

Comparison between Minimally Invasive Transforaminal Lumbar Interbody Fusion and Conventional Open Transforaminal Lumbar Interbody Fusion: An Updated Meta-analysis
por: Xie, Lei, et al.
Publicado: (2016)

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Nijiao, et al.
Publicado: (2023)

Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis
por: Cui, Xiangrong, et al.
Publicado: (2017)

Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis
por: Wang, Chen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n8gma5gpktcl1i68kl11366hpl